

**American Type Culture Collection MTA Addendum
for the
NCI PBCF CONTRACT**



The National Cancer Institute (NCI) Division of Cancer Biology (DCB) supports and facilitates basic research in all areas of cancer biology at academic institutions and research foundations across the United States and abroad. DCB provides funding for research that investigates the basic biology behind all occurrences of cancer. A better understanding of basic cancer biology provides the building blocks to new treatments, clinical trials, and improved understanding of the disease. The mission of the DCB is to ensure continuity and stability in basic cancer research while encouraging and facilitating the emergence of new ideas, concepts, and technologies.

DCB houses programs in both Physical Sciences-Oncology and Cancer Systems Biology. The Physical Sciences-Oncology Network (PS-ON; hereinafter the “Network”) aims to build multi-disciplinary teams to converge the fields of physics, chemistry, mathematics and engineering with cancer biology and clinical oncology to advance our understanding of human cancers and to better define the physical and chemical forces that shape and govern the emergence and behavior of cancer. The Network is comprised of several academic institutions and fosters open exchange of research materials necessary to advance the aims of the Initiative. Complementary to the Network, the Cancer Systems Biology Consortium (CSBC; hereinafter the “Consortium”) utilizes computational analysis and mathematical modeling to describe and understand cancer mechanisms in a deeply multivariate way, and to predict the consequences of interventions on disease. To this end, the NCI has entered into a contract (hereinafter the “Contract”) with the American Type Culture Collection (hereinafter “ATCC”) to serve as the Physical Sciences-Oncology Network Bioresource Core Facility (hereinafter “PBCF”). The PBCF functions as a biorepository and biodistributor to facilitate the distribution of cell lines, biospecimens and related derivative materials and standard operating procedures amongst the Network and Consortium Investigators.

WHEREAS, a Network or Consortium recipient institution (hereinafter a “Recipient Institution”) has signed, or is prepared to sign an ATCC Material Transfer Agreement (“MTA”) with the ATCC for the acquisition of cell lines and related derivative material (hereinafter “Biological Materials”) for research purposes by Recipient Institution’s Network or Consortium Investigator (hereinafter “Recipient Investigator”);

WHEREAS, the parties mutually agree that the proposed use of the Biological Materials by Recipient Institution is for research purposes in accordance with the PBCF Contract;

NOW THEREFORE, the parties agree to this **PBCF Transfer Addendum** (“Addendum”) incorporating the following changes to the ATCC MTA to reflect more specifically the Contract requirements.

1. **Grant of Rights.** Subject to the terms and conditions of this Addendum, the Recipient Investigator shall have the right to make and use such Biological Materials solely for the purposes of the Contract. **Except for Biological Materials using the hTERT technology, by way of non-limiting example, ATCC® CRL-4010™ or ATCC® CRL-4023™ (and as defined on the product information sheet provided by ATCC);** this Addendum allows a Recipient Institution, with written notification to ATCC, to further transfer Modifications and Unmodified Derivatives to the recipient institutions of the Network or Consortium. Such third-party transfers to members of Network or Consortium is solely *provided*, however, that such third-party transfers are (1) for research purposes as outlined in the Contract, and (2) subject to terms of a material transfer agreement essentially consistent with the MTA and this Addendum. Except as specified above, as per the

terms of the MTA, Recipient Investigator(s) may not distribute the Biological Materials for any other reason without ATCC's prior written consent. ATCC retains all rights not expressly granted herein.

2. Record-Keeping. Recipient Investigator will keep and maintain records showing the chain of custody of all Modifications and Unmodified Derivatives received under the Contract. These records will include, but not be limited to, the following information: the name of the cell line (to include Modification and Unmodified Material) transferred; the name of the Network or Consortium Investigators; (receiving and sending the Material) and the date of transfer. Such records will be preserved for at least five (5) years after the date of the termination of this Addendum. The record will be provided annually to the NCI Contracting Officer's Representative who will compile the records from each Network or Consortium Investigator and will provide a comprehensive annual report to ATCC.
3. Terms and Conditions. The Recipient Institution will comply with the terms and conditions of the MTA and this Addendum. Recipient Investigators, in accordance with the terms of the Contract, may deposit modifications and derivative materials that originate from the Biological Material with the ATCC for further distribution to other Network or Consortium Investigators. ATCC, in accordance with the terms of the Contract, may further distribute these modifications and derivative materials to other Network or Consortium Investigators.
4. Acquisition of Biological Materials. In accordance with the Contract, ATCC shall not charge Recipient Institution for the purchase of the Biological Materials. However, ATCC is free to request payment for shipping and handling charges associated with the transfer.
5. Term and Termination. Unless earlier terminated under this Section 5, this Addendum will remain in full force and effect until expiration of the Contract. ATCC may terminate this Addendum if the Contract is terminated or not renewed by the NCI prior to the Contract expiration date. The Recipient Institution may terminate this Addendum at any time upon sixty (60) days written notice to ATCC. In the event of a breach of this Addendum by the Recipient Institution, ATCC will be entitled to terminate this Addendum and require the Recipient Investigator to cease all use and destroy all stocks of the Biological Materials and to provide ATCC with written notice of such fact. Upon termination of this Addendum for any other reason, Recipient Investigator will cease all use of Biological Materials pursuant to this Addendum and shall provide ATCC with written notification of that fact. The exercise by any party of any remedy under this Addendum will be without prejudice to its other remedies under this Addendum or otherwise. The parties acknowledge that any breach by the Recipient Institution of its obligations hereunder may result in irreparable harm to ATCC for which no adequate remedy exists at law, and that ATCC therefore shall be entitled to seek injunctive relief to enforce its rights under this Addendum.

This Addendum incorporates by reference the terms and conditions of the MTA to the extent not expressly modified herein. In the event of any conflict between the terms of this Addendum and the terms of the MTA, the terms of this Addendum shall control.

SIGNATURES ON FOLLOWING PAGE

BY SIGNING BELOW, THE DULY AUTHORIZED REPRESENTATIVE OF EACH PARTY ACKNOWLEDGE THAT THEY HAVE READ AND UNDERSTOOD AND AGREE TO THE TERMS AND CONDITIONS SET FORTH IN THIS MTA ADDENDUM FOR THE NCI PBCF CONTRACT, AS EVIDENCED BY THEIR SIGNATURES BELOW.

PS-ON or CSBC Recipient Institution: _____

For ATCC

By: _____

Name: Stewart N. Davis

Title: Director, Intellectual Property and Licensing

For PS-ON or CSBC Recipient Institution

By: _____

Name: _____

Title: _____

Date: _____

**Read and Understood by
Recipient Investigator:**

By: _____

Name: _____

Title: _____

Date: _____